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To the Editor:
It was a pleasure reading the article
by Mercy George and colleagues in
the Journal.1 I would like to note that
the technique for treating benign sub-
glottic stricture on pages 414 and 415FIGURE 1. Temporary plastic obturator in upper tr
permission.2,3
The Journalof their article was described in previ-
ously published studies.2,3
Figure 1 is a copy of the illustration
used in my article.
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doi:10.1016/j.jtcvs.2010.04.041Reply to the Editor:
We thank Dr Demos for his com-
ment on our article on the management
of pediatric subglottic stenosis with
glottis involvement.
The management of glotto-subglot-
tic stenosis is challenging, and its
surgical management, therefore, has
evolved over the years with descrip-
tions of the surgical technique and its
modifications, along with the use of
stents. The technique we have used in
this large pediatric series is different
from that described earlier by Demos
and colleagues in 1969.1,2 Notably,
this series is the first pediatric
series of its kind. The technique com-
bines a subglottic resection and thyro-achia and glottis fixed with wire. Reprinted with
of Thoracic and Cardiovascular Surgetracheal anastomosis with a posterior
cricoid split and costal cartilage graft
for glotto-subglottic stenoses. This op-
eration was named ‘‘extended partial
cricotracheal resection.’’ The LT-
Mold prosthesis is also different in
that it calibrates the supraglottic and
glottic spaces in the abducted position
of the vocal cords, while restoring a tri-
angular shape to the glottis with a sharp
anterior laryngeal commissure.3 All
currently available stents are round
or cigar shaped and do not restore a tri-
angular glottis, especially in the case of
vocal cord synechia or grade IV trans-
glottic stenosis. The use of the LT-
Mold prosthesis has significantly
diminished the incidence of postopera-
tive granulations that require repeat
endoscopic/open procedures. This
study was therefore a synthesis of our
experience of complex pediatric
glotto-subglottic stenosis that docu-
ments the evolution of the technique
with an emphasis on the silicone
LT-Mold.
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To the Editor:
What is the future of cardiac surgery?
This question undoubtedly brings to
mind images of fancy new technology,
robots, stents, lasers, and other mini-
mally invasive or futuristic techniques.ry c Volume 140, Number 3 723
Letters to the EditorHowever, the real question that our spe-
cialty needs to address is this: How
should cardiac surgery deal with the
fact that technology changes rapidly,
that the potential therapeutic options
for patients increase faster thanprospec-
tive trials can evaluate them, and that
each year patients who undergo cardiac
surgery continue to be sicker, older, and
at higher risk for complications?
Currently, significant and often un-
perceived conflicts of interest exist
for everyone involved, and it is diffi-
cult for the patient to make a well-
informed opinion. As patients get
sicker and hear about advancing tech-
nology, they are more likely to have
unrealistic expectations. New technol-
ogy is often offered to patients more as
part of amarketing tool than as a proven
therapy.Often, both the surgeon and the
cardiologist will be reimbursed from
a newer hybrid technique. Conflict of
interest can arise from the need tomain-
tain referral patterns and maintain reim-
bursement. The patient is unlikely to
argue against a smaller incision involv-
ing a newer approach, even if the newer
approach has not been proven to be as
good as the current standard of care.
Dr Alec Patterson, President of the
American Association of Thoracic
Surgery, highlights in his presidential
address a need for a change in our pro-
fessional behavior from the individual
to the team approach to care. This
change is likely to be a solution to these
potential conflicts. Patients with cardio-
vascular disease should be offered the
benefits of a multidisciplinary team ap-
proach. This approach has existed for
many years (eg, tumor boards and
transplant selection conferences) but
is not routinely practiced in cardiovas-
cular surgery. A multidisciplinary ap-
proach requires that a regular meeting
take place at which all of the consul-
tants are present to review the data, dis-
cuss what each can offer, and propose
a therapeutic plan. Such an approach
lays the groundwork for the patient to
benefit from the expertise of the entire
team and the foundation from which
all new technologies and therapies can724 The Journal of Thoracic and Cbe evaluated as they continuously sur-
face. The multidisciplinary approach
is to medicine what the scientific
method is to research: the best defense
against conflict of interest.1 Thus this
approach will always keep the patient’s
best interest at the center of our focus.
Octavio E. Pajaro, MD, PhD
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THERAPY NECESSARY IN
BIOPROSTHETIC VALVES?
To the Editor:
We read with great interest the con-
tribution by ElBardissi and associates1
addressing a controversial issue: the
need for early antithrombotic therapy
in patients with tissue valves. The au-
thors sought to determine whether
this therapy was necessary in patients
in sinus rhythm with a tissue valve in
the aortic position. Their sample of
861 patients is large enough to con-
clude that early anticoagulation after
isolated aortic valve replacement with
a tissue valve does not reduce the
risk of thromboembolism.
The authors are right as to whether
anticoagulation is a must or not in this
type of patients and refer to the recent
American Heart Association/American
College of Cardiology and European
Society of Cardiology recommenda-
tions. The impactful and classic paper
byHeras and colleagues,2 summarizing
an experience from the Mayo Clinic,
led to the consideration of anticoagula-
tion as an adjunct of choice based on
a retrospective analysis during a long
period of time with special focus on pa-
tients with no antithrombotic therapy.
The results of the study of ElBardissi
and associates1 give additional light to
previous publications confirming thatardiovascular Surgery c September 201the 90-day risk of thromboembolism
was 5% in both groups with or without
anticoagulation. The authors identified
classic risk factors for thromboembolic
complications, such as advanced age,
female gender, short stature, smoking,
and a 19-mm valve. We fully agree
with this and their final conclusion.
The authors refer to thromboembo-
lism and the lack of randomized studies
to confirm their conclusion. That was
our concern when we designed our pro-
spective and randomized pilot trial.3 In
this cooperative pilot study, 193 pa-
tients were randomized to acenocu-
marol and triflusal (an antiplatelet
agent) for primary prevention of throm-
boembolism early after tissue valve im-
plantation; 93.8% were aortic valves.
We3 aimed at evaluating the efficacy
and safety of antiplatelet therapy versus
acenocumarol with the primary end
point of a composite of thromboembo-
lism, hemorrhage, and valve-related
mortality. The results of our random-
ized trial were that the rate of thrombo-
embolic events was not significantly
different among groups, thereby con-
firming that antiplatelet therapy was
an equally protective strategy. In addi-
tion, there was a statistically significant
difference favoring the antiplatelet
group in terms of hemorrhagic events.
The conclusions of this first reported
randomized trial comparing antiplatelet
versus anticoagulant therapies were
that there was a safer profilewith signif-
icantly lower bleeding in the antiplate-
let group. The results by ElBardissi
and coworkers1 are consistent with
these data in terms of protection against
thromboembolic events. Despite some
limitations in our design that have
already been addressed, we strongly
believe that early anticoagulationmight
not be the ideal therapy considering the
currently accumulated experience that,
of course, includes this very appropri-
ate and updated experience by ElBar-
dissi and colleagues.1
Finally, similar conclusions were
recently reached by Brueck and
associates.4 They also addressed
patients with no risk factors for0
